Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.614 USD | +2.66% | -13.80% | +80.19% |
09/05 | Monopar Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
16/04 | Monopar Therapeutics Files Provisional Patent for New MNPR-101 Construct | MT |
Evolution of the average Target Price on Monopar Therapeutics Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Monopar Therapeutics Inc.
JonesTrading Institutional Services | |
HC Wainwright | |
Maxim | |
EF Hutton | |
Roth MKM | |
Roth Capital Partners |
EPS Revisions
- Stock Market
- Equities
- MNPR Stock
- Consensus Monopar Therapeutics Inc.